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ABSTRACT: The performance of supramolecular nanocarriers as drug delivery systems depends on their stability in the complex
and dynamic biological media. After administration, nanocarriers are challenged by physiological barriers such as shear stress and
proteins present in blood, endothelial wall, extracellular matrix, and eventually cancer cell membrane. While early disassembly will
result in a premature drug release, extreme stability of the nanocarriers can lead to poor drug release and low efficiency. Therefore,
comprehensive understanding of the stability and assembly state of supramolecular carriers in each stage of delivery is the key factor
for the rational design of these systems. One of the main challenges is that current 2D in vitro models do not provide exhaustive
information, as they fail to recapitulate the 3D tumor microenvironment. This deficiency in the 2D model complexity is the main
reason for the differences observed in vivo when testing the performance of supramolecular nanocarriers. Herein, we present a real-
time monitoring study of self-assembled micelles stability and extravasation, combining spectral confocal microscopy and a
microfluidic cancer-on-a-chip. The combination of advanced imaging and a reliable 3D model allows tracking of micelle disassembly
by following the spectral properties of the amphiphiles in space and time during the crucial steps of drug delivery. The spectrally
active micelles were introduced under flow and their position and conformation continuously followed by spectral imaging during
the crossing of barriers, revealing the interplay between carrier structure, micellar stability, and extravasation. Integrating the ability
of the micelles to change their fluorescent properties when disassembled, spectral confocal imaging and 3D microfluidic tumor blood
vessel-on-a-chip resulted in the establishment of a robust testing platform suitable for real-time imaging and evaluation of
supramolecular drug delivery carrier’s stability.
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■ INTRODUCTION
Supramolecular nanocarriers, such as liposomes or micelles, are
broadly investigated as potential drug delivery systems (DDS)
for cancer therapy.1,2 Since Doxil, a liposome-encapsulated
Doxorubicin, was approved in 1995,3 the therapeutic efficacy of
many nanosystems with different chemical features has been
tested. However, low accumulation of the nanoparticles (NPs)
in the solid tumor is still a major issue4 and one of the key
reasons for failures in clinical trials. One of the main challenges
with the use of supramolecular nanocarriers is to control their
assembly−disassembly equilibrium, which determines in vivo
success. The exposure to physiological environment affects the
properties and decreases the number of fully assembled NPs
arriving to the target site.5 Therefore, it is important to design
nanosystems that are stable once injected into the body, and
“smart” to free up the cargo when the target is reached.
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Right at the injection site, the NPs are subjected to a high
dilution, interactions with serum proteins, and shear stress in a
blood vessel, which favor their disassembly and lead to
premature drug release into the bloodstream, causing systemic
cytotoxicity or uncontrolled drug distribution.6−8 Internal walls
of blood vessels are layered with endothelial cells (ECs),
connected by characteristic tight junctions, which create a
physical barrier, allowing the diffusion of only small molecules.9
Interactions with ECs membrane, upon NPs extravasation, can
further compromise their stability. Nowadays, most of nano-
particles-based DDS rely on the enhanced permeability and
retention (EPR) effect.10 During EPR, the endothelial junctions
are impaired, creating gaps that allow larger molecules to leave
the systemic circulation,11 thus opening an escape route for the
NPs.12 Particles able to extravasate through the “leaky”
endothelial barrier (EB) arrive to the extracellular matrix
(ECM) and the cancer cells. The ECM can differ in pH and
shear stress comparing to the blood vessel,13 and its components
can affect the NPs assembly equilibrium.5 The predictability and
understanding of the stability of supramolecular assemblies
Figure 1. Schematic representation of the model. (a) Molecular structure of the amphiphilic PEG−dendron hybrid polymers (left). Fluorescence
emission graph for micelle−monomer equilibrium (right). In magenta, monomer (fully disassembled structure) and in green (fully assembled),
micelle. (b) Schematic illustration of the top view of the model, with the reconstructed barriers marked as (1−4), two main regions (A, blood vessel
channel and B, ECM model), and a cross-section indicated by dashed line for the projection of panel e. (c) 3D drawing of the microfluidic chip
including inlets and outlets of each channel. A and B indicate two main compartments of the model: the blood vessel and ECM and the dashed-line
marks area for the projection of the view in panel d. (d) Top view illustration of the microfluidic chip indicating the localization of the (A) blood vessel
model channel and the (B) ECM model. The channel A is under continuous perfusion as schematically represented. (e) Cross-section illustration of
the model (A and B, blood vessel/ECM model channels, respectively) and the scheme of the real-time imaging setup. (f) Zoom into the 3D
representation (from panel c) showing the perspective of the channels before and after the complete model reconstruction. It illustrates howHUVECs
line the blood vessel model channel covering the pillars and the collagen gel scaffold, forming a vertical endothelial barrier.
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within these changing conditions can pave the way to an
improved design of nanosystems to be translated into the clinics.
Because of the difficulties in real-time monitoring of NPs in
physiologically relevant milieu, many aspects are not addressed
when screening DDS candidates. Recently, a Förster resonance
energy transfer (FRET) approach was used to follow the
disassembly of supramolecular structures in blood serum,14−17
and in animal models,18 by encapsulation or covalent attach-
ment of a FRET fluorophore pair into one micelle. In our recent
work, we employed PEG-Dendron amphiphiles that were
functionalized with a spectral-shifting coumarin to track the
stability of micelles in serum and cells.19 These micelles can self-
report their disassembly by the change of their fluorescent
spectrum to the intrinsic emission of the labeling coumarin dyes.
The change in assembly was detected in complex media using
spectral imaging, enabling the NPs stability study in space and
time. Nevertheless, the in vitro assays consist mainly of 2D
systems, which despite being high throughput and rapid, do not
provide complete information reflecting the in vivo conditions.20
In the last years, microfluidic 3D models have been extensively
used to study cancer cells migration,22−25 vascularization and
angiogenesis,26−29 EB permeability,30−32 impact of 3D cell
architecture,33−35 and tumor penetration.34,36−38 Recently,
more complex blood vessel models have been designed to
assess the differences in nanoparticles permeation in various
conditions,13,30,31,39,40 demonstrating an impact of cancer cells
on the endothelial permeability. However, in majority of them,
only the intervals or the end time point of nanoparticles
incubation are reported, lacking the important time-resolved
information.
Herein, we address this challenge by combining a real-time
spectral confocal imaging of polymeric, self-reporting micelles,
which are perfused through tumor blood vessel model in a
cancer-on-a-chip platform, to map their stability when
encountering biological barriers. By evolving conventional 2D
studies into more adequate 3D models,33,41,42 we aim to expand
our previous work19 and provide additional screening before use
of animal models.21,43−45
■ RESULTS AND DISCUSSION
The System: Amphiphilic PEG-Dendron Micelles and
Microfluidic Cancer-on-a-Chip. Three amphiphilic PEG-
dendron hybrids, differing by their lipophilic end-groups in the
hydrophobic block, were synthesized and characterized
Figure 2. Functionality of the endothelial barrier model. (a) Transmission image showing complete tumor blood vessel-on-a-chip model with
HUVECs lined lateral channel (left part of the chip) and adhering ECMmodel channel (right) with gel embedded HeLa spheroid. Scale bar 200 μm.
(b) Transmission image of the lower and upper plane of the blood vessel model covered with confluent HUVECs monolayer. Scale bar 100 μm. (c)
Confocal image ofHUVECs confluentmonolayer (red, actin; blue, nucleus; green, ZO-1). Scale bar 20 μm. (d) 3D reconstruction of confocal image of
vertically grown HUVECs layer on the scaffold of collagen gel between the chip’s microposts (red, actin; blue, nucleus; green, ZO-1); scale: axis ticks
separation 40 μm, blue triangles represent base of the microposts. (e) Confocal images of actin stained (green) HUVECs in static (top) and perfused
(bottom) blood vessel model channel and graph of actin filaments organization, demonstrating alignment under the flow and random orientation in
static culture. (f) Epifluorescent microscopy 3D reconstructed image of continuously perfused 10 kDa Dextran through the endothelialized blood
vessel model channel at a time point 10 min. Scale bar 150 μm.
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following the previously reported methodology;19,46 the
structures are shown in Figure 1a. The amphiphiles were
labeled with a responsive dye, 7-diethylamino-3-carboxy
coumarin, which forms an excimer when the hybrids self-
assemble into micelles, resulting in a red-shift of the dye
emission spectra, allowing to discriminate the assembled state
from the disassembled state, as shown in Figure 1a. The
responsive properties of these micelles, studied in the presence
of serum proteins, HeLa cells, and at physiologically relevant
temperature (37 °C), have been previously demonstrated.19
Here we study the stability of these nanostructures in a cancer-
on-a-chip platform and compare the results to the previously
reported behavior in 2D cell culture.
In the cancer-on-a-chip model, we recapitulate the four
important barriers that the micelles will have to overpass when
injected into the body: (1) the flow of the blood vessel; (2) the
endothelial barrier; (3) the ECM; and (4) the tumor spheroid
(Figure 1b). To recreate this environment in a microfluidic
platform, we used the 3D cell culture chip developed in Kamm’s
Lab and currently available commercially.47 It consists of three
microfluidic channels: the central channel of 1.3 × 0.25 mm2 (w
× h) and the two lateral media channels of 0.5 × 0.25 mm2 (w ×
h), as represented in Figures 1c and S1a. The middle channel is
separated from the two lateral channels by rows of triangular
microposts distant by 100 μm from one another, as shown in
Figure 1c and f. These posts are designed to contain the
unpolymerized gel (spheroids + collagen) in the central channel,
by ensuring adequate surface tension, preventing gel leaks. In
our model, one of the lateral channels represents the blood
vessel and the middle channel recreates the ECM with
embedded tumor spheroids as shown in the Figure 1d.
Human umbilical vein endothelial cells (HUVECs) seeded in
the lateral channel, lined it, and formed a lumen-like geometry,
creating a vertical endothelial wall on the collagen gel scaffold
(Figure 1e,f).
The created EB separates the inner lumen of the blood vessel
model from the ECM channel, where we embedded preformed
HeLa spheroids into the Type 1 Collagen Gel (Figure 1f). The
coculture of endothelial and cancer cells in the same systems
adds complexity to the model; therefore, growth kinetics of
HeLa cells and HUVECs were evaluated to determine the
optimal medium for the healthy growth of both cell lines (see
Supporting Figure S2). Overall, we recreated elements of tumor
microenvironment in cancer-on-a-chip, where micelles stability
can be evaluated during unidirectional perfusion through the
blood vessel model channel. The parallel channel geometry of
our platform enables continuous imaging of the nanocarrier
interactions with the indicated barriers, as represented in Figure
1e. Once the tumor blood vessel model was recreated
(continuously perfused with cell culture medium at 37 °C and
5%CO2), the chip was placed in an optical confocal microscope,
at 37 °C, and reconnected to the perfusion system to track the
assembly state of Hybrids 1−4 (see representation in Figure 1e
and SI Supporting Videos).
Characterization of Reconstructed Barriers in Micro-
fluidic Cancer-on-a-Chip Model. To validate our model, first
we characterized the formation of an endothelial barrier created
in the lateral channel. The magnified transmission image of the
blood vessel channel and adjacent ECM channel with embedded
HeLa spheroid (Figures 2a and S3) demonstrates the complete,
prepared chip after 3 days of unidirectional medium perfusion.
HUVECs are present in both the upper and lower plane of the
blood vessel model, as shown in the transmission images of
Figure 2b, and the formation of confluent endothelial monolayer
lining the lumen was further validated by fixing and staining the
cells, as shown in confocal image in Figure 2c and d, where actin
(red), nucleus (blue), and formation of tight junctions (green)
can be observed. The endothelial cell to cell contact results in the
expression of zonula occludens-1 (ZO-1) protein, which is
essential to form these junctions in a healthy endothelial
barrier.48 Moreover, 3D reconstruction of confocal imaging
demonstrates the presence of the EB between themicroposts, on
the gel scaffold (Figure 2d), physically separating the lumen of
the vessel from the ECM channel, mimicking the in vivo barrier.
Figure 3. (a) Transmission image of collagen gel-embedded HeLa cells conformed into 3D spheroid. Scale bar 50 μm. (b) Transmission images
demonstrating proliferation of a gel-embedded spheroid from the preparation up to 3 days in perfused culture. Scale bar 100 μm. (c) Graph
demonstrating size progression of gel embedded spheroids after 1 and 3 days of perfused culture, calculated based on diameter measured in 10 different
chips, average with standard error bars. (d) Confocal image of stained HeLa spheroid with calcein (live cells: green) and Propidium iodide (dead cells:
red). Scale bar 50 μm.
ACS Applied Bio Materials www.acsabm.org Article
https://dx.doi.org/10.1021/acsabm.0c01209
ACS Appl. Bio Mater. 2021, 4, 669−681
672
Additionally, HUVECs exhibited parallel alignment to the flow
direction as a result of the created shear stress49,50 (Figure 2e).
In contrast, cells cultured in static conditions showed random
filament organization, as observed previously.51 Finally, we
tested the structural integrity of the HUVECs barrier by
measuring the retention of fluorescently labeled 10 kDaDextran,
continuously perfused through the endothelialized channel. The
fluorescence signal was detected in the lumen of the EB channel
but not in the collagen gel (Figure 2f), indicating proper
functionality of the endothelial barrier. However, a low gradual
penetration of the Dextran into the ECM was observed after 30
min (Supporting Figure S4), similar to other reported
studies.47,52−54 Altogether, these measurements indicate the
formation of a functional EB with good structural integrity.
Finally, we characterized the ECM central channel with gel
embedded HeLa spheroids. The transmission microscopy
allowed us to observe the 3D spheroid conformation (Figure
3a) recapitulating aspects of geometry present in physiological
conditions. This arrangement implies less available surface area
per cell than in 2D cell culture models; it also alters cell
proliferation rate and its overall functionality.20,34,55 The growth
of prefomed spheroids, cocultured in the perfused chip together
with HUVECs, is demonstrated in Figure 3b. The spheroids
with size of 100± 50 μmwere introduced into the chip, and after
3 days of culturing, they grew on average by 220% of their initial
size, as shown in graph of Figure 3c. HeLa viability was
confirmed with a live/dead staining assay, revealing that the cells
were viable throughout the spheroid after 3 days of culture
(Figure 3d), indicating good nutrients and oxygen diffusion.
Given the size of our spheroid after 3 days, we expected to
observe high viability, as the phenomena of necrotic core
Figure 4. Extravasation of PEG-dendron hybrids in nonendothelialized, healthy and cancer models. (a) Confocal image of hybrid 1 extravasation in a
(i) control chip (no EB), (ii) a healthymodel, and (iii) cancer model. The images show emitted intensity between 446 and 700 nm, which include both
the monomer and micelle signal. Scale bar 100 μm. Quantification of the normalized micelle fluorescence intensity measured in a rectangular area
between two neighboring posts, indicating the penetration from the blood vessel model channel into the ECM part, plotted for the i−iii models.
Vertical dotted line indicates the localization of the EB. (b) Confocal image of hybrid 4 (monomer) extravasation in the three corresponding models.
Scale bar 100 μm. Quantification of the normalized monomer fluorescence intensity, measured in a rectangular area between two neighboring posts,
indicating the hybrid 4 penetration from the blood vessel model channel into the ECM part, plotted for the i−iii models. Vertical dotted line indicates
the localization of the EB. (c) Confocal image of HUVECs monolayer lining the healthy (left) and cancer (right) blood vessel channel model. Actin
(red) and ZO-1 (green). Scale bar 20 μm. Quantification of the fluorescence intensity over the two marked rectangular areas indicated in the images
(on the left). The spikes in the healthy model (yellow) originated from higher expression of ZO-1 in contrast to lower expression in the cancer model
(green).
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development is reported in the spheroids beyond 500 μm
diameter.56−59
Overall, we adapted a microfluidic platform to a 3D dynamic
tumor microenvironment, including a perfusable blood vessel
model, and cancer cells conformed into spheroid.
Increased Extravasation of Micelles Is Induced in
Tumor Blood Vessel Model. Having established our tumor
blood vessel-on-a-chip model, we investigated the ability of the
micelles to penetrate the EB into the ECM channel. Previous
studies using microfluidic models reported enhanced perme-
ability of endothelial cells when exposed to specific molecules,
such as TNF-α39 or when cocultured with cancer cells,31 leading
to the formation of “leaky vessels”, representing one of the
features of the EPR effect. However, most of these microfluidics
models were used for studying only the selected or final time
point of nanoparticles penetration. Herein, taking advantage of
the characteristics of the chip, we could continuously monitor
the perfusion of our micelles in three different experimental
conditions: (i) no HUVECs (nonendothelialized lateral
channel) as negative control; (ii) HUVECs barrier (healthy
endothelialized blood vessel model), and (iii) HUVECs barrier
with HeLa spheroids embedded in the ECM (tumor blood
vessel model).
First, we tested the micelle ability to cross the EB, perfusing
the hybrid 1 into the three models (i−iii) and quantifying the
fluorescence intensity, in the blood vessel model and ECM part,
as plotted for the i−iii in Figure 4a. A constant amount of the
fluorescence was immediately detected in the collagen gel in case
of lack of the EB (i), which demonstrates that our NPs freely
diffuse through the ECM.5 On the contrary, the majority
(>90%) of hybrid 1 was retained in the healthy blood vessel
model channel (ii) for more than 30 min of continuous
perfusion. Meanwhile, a gradual diffusion of the hybrid into the
ECMwas observed in the tumor blood vessel model (iii). These
results indicate that the HUVECs monolayer in the healthy
model fulfills the barrier function and limits the hybrid
penetration into the ECM. However, this function is affected
by presence of HeLa spheroids in the gel. Our observations
resemble experiments performed by Tang and co-workers where
coculture of cancer endothelial cells with breast cancer cells
increased the permeation of nanoparticles through the EB.31
Interestingly, we hypothesized that the ∼10% of the hybrid
detected in the ECM of the healthy model (ii) could originate
from the infiltration of the monomer (disassembled form ∼6−7
kDa, assembled micelle ∼20 nm), small enough to pass through
the healthy EB.47,60 To investigate this further, we perfused
hydrophilic hybrid 4, which has four hydroxyl end-groups (does
not self-assemble into micelles),19 into the same three models
(i−iii) as hybrid 1. As expected, Figure 4b shows that the
monomer penetrated the ECM instantly in the control (i) and
Figure 5. Space and time-resolved stability of hybrid 1. Representative images, selected from the 10 repetitions of experiments within hybrid 1 in the
tumor blood vessel model. (a) Ratiometric confocal images of real-time monitored micelle (green) and monomer (magenta) at reconstructed barriers
(1, blood vessel model channel; 2, HUVECs barrier; 3, ECM; 4, HeLa spheroid) during continuous perfusion of the hybrid 1, scale bar 15 μm. Relevant
time points were selected for representative purposes. (b) Time-resolved intensity of fluorescence signal (A.U) originating from the sum of both:
micelle and monomer channels at each barrier (1−4) of the presented images. (c) Normalized ratio of fluorescence signal between micellar and
monomer form monitored in time at different barriers. Green dashed line indicates the ratio of fully formed micelles in equilibrium, and the magenta
dashed line indicates the ratio of fully disassembled (monomer) form.
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the cancer (iii) models, but some infiltration into the ECM was
also observed in the healthy (ii) one. Specifically, HUVECs
barrier partially retained the monomer for 25 min of continuous
perfusion, limiting its concentration in the gel to less than 40% of
its intensity in the perfused channel. It is worth noting that after
5 min of perfusion, the hybrid 4 could already be detected in the
gel of the healthy blood vessel model (Supporting Figure S6).
However, the penetration into the ECMwas far more significant
and immediate in the HeLa cells cocultured chip. Overall, we
hypothesize that the monomer form can gradually cross into the
ECM region of the healthy blood vessel model due to its small
size, permitting the paracellular transport.
We visually determined the morphological effect of
coculturing cancer cells on the structural integrity of the
endothelial monolayer to understand if a loss of EB integrity was
the reason for the increased micelles permeation into the ECM
in the cancer model. Tight and adherent junctions are the crucial
structural elements formed between endothelial cells, regulating
paracellular diffusion and restricting the permeation of
molecules bigger than ∼2 nm.61 To confirm that the enhanced
permeability of the EB in ourmodel was induced by the presence
of HeLa spheroids, we prepared the chips as mentioned
previously, and after 3 days of medium perfusion, the cells
were fixed, ZO-1 protein stained, and quantified as shown in
Figure 4c and Supporting Figure S7. ZO-1 was clearly and
uniformly expressed between HUVECs of the healthy model;
however, the expression was reduced in the HeLa spheroids
cocultured model. It indicated that cancer cells impacted the
HUVEC cell−cell interaction and the tight junction formation,
therefore explaining the enhanced permeability in our cancer
models. Similar findings were reported by Kaji et al.,62 where
HUVEC and HeLa coculture affect the endothelial cells growth
through the direct cell−cell contact as well as transmission of
information via culture medium (paracrine communication). In
that study, the cytokines excreted by HeLa repulsed HUVECs
and released reactive oxygen species, which led to malfunction
and death of HUVECs, resulting in leakiness of the EB.
However, it is worth noting that in our study there was a certain
heterogeneity in the permeation of micelles out of the tumor
blood vessel model. We observed that small variations in the
number of spheroids (or their distribution) affect the EB
retention capacity, potentially resulting in a variable concen-
tration of signaling molecules (see Supporting Discussion).
These observations may be reflecting one of the key features of
the EPR effect, of which the heterogeneity has been extensively
discussed recently, and attributed to the stage of the diseases.63
Time- and Space-Resolved Micelle Stability Revealed
in 3D Tumor Microenvironment Model. The aim of our
work was to study the stability of our micellar systems when
introduced into the microfluidic 3D model. Previously the
micelles and monomer were detected in the presence of serum
proteins and their internalization pathway identified thanks to
their self-reporting capabilities compatible with confocal
fluorescence microscopy.19 Herein, we hypothesized that the
added complexity and dynamicity of the blood vessel model may
induce premature disassembly due to multiple interactions. To
evaluate these critical interactions, we continuously perfused
micelles of hybrid 1 (the most stable system), in full culture
medium at 15 μL/min and 37 °C into the blood vessel model
channel. During perfusion, we continuously monitored the
micelles’ stability in key regions: the blood vessel model channel,
the endothelial barrier, the ECM, and the HeLa spheroids,
providing real-time stability information as shown in Figure 5
and the Supporting Videos.
In the first minutes of perfusion, fluorescence was detectable
only in the blood vessel model channel (Figures 5a,b) and
indicated the presence of assembled micelles (Figure 5c).
Hybrid penetration into the depth of the ECM was observed
over time. After 15 min of continuous flow, the hybrid started to
reach the EB, and we could observe that the disassembled form
prevailed in passing through the wall and entering the ECM by
detecting the monomer emission (magenta). After 25 min, we
observed the assembled form traversing the EB, while the deep
penetration into ECM was still achieved mostly by the
disassembled polymers. This observation could be attributed
to two factors: (i) the micelles progressively overcame the
endothelial barrier or (ii) the monomer form, which entered the
ECM through the EB previously, accumulated, and reached the
critical micelle concentration (CMC), reassembling into
micelles. Figure 5b demonstrates that both, micelle and
monomer, coexist at the EB and in the ECM with the mean
ratio 0.6 and 0.4, respectively. The assembled structures were
detected in the surroundings of the spheroids after more than
half an hour of the continuous perfusion. Surprisingly, after 1 h,
we observed only weak penetration of the hybrid 1 into the
depth of the HeLa spheroids, similarly to 2 h of constant
perfusion (Supplementary Figures S8 and S9). In our previous
2D cell internalization studies, the hybrids were detected inside
the cell already after 10 min; meanwhile, in the current work,
only a small fraction of the disassembled form was detected in
the outer layer of the spheroid.
Interestingly, we observed a stabilization of monomer/micelle
equilibrium in the monitored regions after 1 h from the
beginning of the perfusion, except for the spheroid area. Hybrid
1, detected as a monomer in contact with HeLa cells, was a
contrasting observation comparing to our previously reported
internalization behavior in 2D cell cultures, where the assembled
hybrid 1 was taken up by HeLa cell via endocytosis, and its
disassembly progressed in time.19 This discrepancy can be
attributed to the spheroid form of the HeLa, promoting different
endocytosis process, favored in the new 3D cells confluency and
conformation. Other works, highlighting the importance of
going beyond 2D cell culture models, investigated the
penetration of nanosystems into tumor spheroids as a function
of nanocarrier size, shape, charge, and functionalization.36,64,65
Likewise, the penetration of cross-linked and non-cross-linked
micelles has been compared, showing an improved result for the
cross-linked (more stable) ones.66−68 Therefore, we hypothe-
sized that the lower spheroid penetration in our model can be
caused by a premature disassembly in the periphery of the
spheroid leading to a different outcome than reported in the 2D
static monoculture. It underlines the importance of model
selection in rational evaluation and optimization of supra-
molecular systems for drug delivery.
Stability of Hybrids Dictates Their Infiltration/Extrav-
asation. Finally, we investigated the interplay between
molecular structure, micellar stability, and their ability to
extravasate. Therefore, we compared the stability of three
hybrids, with decreasing length of the hydrophobic end-groups,
from hybrid 1 to hybrid 3. In our previous 2D studies, we
demonstrated that the hybrid 1 was stable in the presence of
serum proteins and upon dilution; meanwhile, the stabilities of
hybrid 2 and 3 were similar when diluted with serum; however,
their disassembly kinetics were significantly different. While
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hybrid 3 disassembled rapidly upon dilution, hybrid 2 needed
hours to reach equilibrium.
To understand how these differences in thermodynamics and
kinetic stability are reflected in a more complex model, we
perfused each hybrid solution (in full culturemedia) through the
blood vessel model channel during at least 30 min. In Figure 6,
we show representative images, demonstrating observations for
the sets of hybrid−cancer model experiments, where an
individual chip was perfused only with one hybrid. We chose
two different areas of each chip-hybrid set, taking the distance of
the HeLa spheroid to the HUVECs barrier as the selection
criterium, to illustrate the different behavior we observed. HeLa
spheroids less than 400 μm from the EB were considered as
“close” to HeLa and EB regions at a radius of at least 1 mm were
considered as regions “far” from HeLa, as reported in Figure 6
and Supporting Figure S10. We observed extravasation of all
hybrids 1−3 through the EB when HeLa spheroids were located
close to HUVECs (Figure 6b). However, in the distant regions
(far HeLa), only hybrid 3 (which has the least hydrophobic
dendron) was able to significantly extravasate to the ECM. Thus,
we concluded that the endothelial barrier “leakiness” can be
heterogeneous, depending on the amount, distance, and
distribution of tumor spheroids in the ECM.
Monitoring stability of these three hybrids (Figure 6a and c,
and Supporting Videos) was based on the ratios between the
emitted intensity of the coumarin dye at 480 and 550 nm (the
disassembled and assembled state respectively). Hybrid 1
appeared as a micelle in the blood vessel model channel, with
mean ratio of fluorescence signal between the both forms equal
to 1 (indicative of the micelle), while slight disassembly of
hybrid 2 and significant disassembly of hybrid 3 were observed,
with mean ratios of 0.8 and 0.5, respectively. Our previous study
showed that hybrids 2 and 3 were slightly unstable in the
presence of serum proteins, but their degree of disassembly
based on the fluorescent ratio was equal. Therefore, we
hypothesized the enhanced disassembly of hybrid 3 is not only
Figure 6. Stability of hybrids 1−3, perfused through a tumor blood vessel models with different EB distance to theHeLa spheroid (close: < 400 μm, far:
> 1 mm). (a) Ratiometric confocal images of the different hybrids perfused through the chip in two regions. Hybrids 1 and 2 are shown at two different
time points: less than 15 min and after 30 min of continuous perfusion; hybrid 3 demonstrated at one time point due to its rapid penetration through
the EB. Scale bar 75 μm. (b) Summed up fluorescence intensity originating from the monomer and the micelle channels. Intensity was measured in the
blood vessel model channel and in the ECM region. (c) Normalized ratio of fluorescence signal between micellar and monomer form for each hybrid
and in each region. Green dashed line indicates the ratio of fully formed micelles in equilibrium, and the magenta dashed line indicates the ratio of fully
disassembled (monomer) form.
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due to interactions with serum proteins but also caused by the
perfusion. This result indicates that the flow-induced shear stress
can drastically affect the stability of supramolecular nanocarriers.
Furthermore, we monitored the stability of each hybrid at the
previously defined barriers and observed significant differences
among them. Interestingly, in regions far from spheroids, only
the monomeric form of hybrid 3 was able to efficiently
extravasate. This phenomenon could occur due to the increased
disassembly of the micelle in contact with the HUVEC barrier,
which allowed the monomer to (i) paracellularly extravasated
due to its small size or (ii) transcellularly cross the EB. In
contrast to that, hybrid 3 crossed the EB in the semiassembled
state in the regions close to HeLa (as it appeared in the blood
vessel channel), probably due to the disappearance of the tight
junctions in the HUVEC barrier. On the other hand, the
extravasation of hybrid 2 in regions close to HeLa had a time-
dependent response; first only monomer crossed the EB and the
micelles were detected in the ECM after more than 30 min.
Finally, we observed that hybrid 1 behaves similarly to the
hybrid 2, where monomer molecules extravasated first, followed
by the later penetration of the assembled micelles. Interestingly,
while hybrids 2 and 3 rapidly accumulated in the endothelial
barrier only as a monomer, hybrid 1 monomeric form
accumulated at the EB only in areas far away from the HeLa
cells. Previously, in 2D cell culture, hybrids 3 and 2 internalized
as monomer, and the hybrid 1 internalized as a micelle and
disassembled over time.19 Overall, we could correlate the
interplay between stability of the micelles and their performance
in a 3Dmodel as well as their ability to extravasate and reach the
cancer cell regions.
■ CONCLUSIONS
In the present work, we combined spectral confocal imaging and a
microfluidic cancer-on-a-chip model as a new approach to study the
stability of supramolecular nanocarriers. The fluorescence properties of
ourmicelles allowed tracking of their assembly state across the changing
conditions of the reconstructed elements of tumor microenvironment.
The results show the formation of functional endothelial barrier in a
lumen of the blood vessel model and appearance of leaky vasculature in
the coculture with cancer cells. The permeable endothelial wall displays
heterogeneity, dependent on the number and distance of HeLa
spheroids, resembling to some extent the in vivo pathologies of many
tumors.
We obtained a precise and direct information about the performance
and stability of the micelles in each of the barriers, thanks to the time
and space-resolved imaging. We reported the ability of the most stable
hybrids 1 and 2 to extravasate from the blood vessel model as assembled
micelles, while the shear stress and interactions with the EB induced
disassembly of the hybrid 3. Therefore, we believe these two micelles
are the best candidates to be used as DDS in vivo. However, we observed
the loss of stability of hybrid 1 in proximity of the spheroids, as well as a
poor penetration into its depth, which indicated a need for
improvement to achieve good in vivo efficacy.
Our approach, combining spectrally responsive supramolecular
structures with a cancer-on-a-chip platform, has the capacity to provide
new knowledge about nanoparticles performance, stability, and
accumulation in tumor, which is essential to bridge the gap between
in vitro and in vivo testing of new drug delivery systems.
■ MATERIALS AND METHODS
Microfluidic Device and Setup. Microfluidic 3D culture
chip DAX-1 (AIM Biotech) was used as a platform to
reconstruct tumor microenvironment (blood vessel model
channel and ECM with embedded spheroids). LUC-1
connectors (AIM Biotech) were used to connect the chip inlets
with luer connector ended PTFE tubing to facilitate the
continuous perfusion. The other end of the tubbing was
connected to a syringe placed in a double syringe pump (Nexus
Fusion 200) and filled with HUVEC (EndoGRO, Millipore)
basal medium, used to constantly perfuse the chip for 48−72 h.
Cells and Reagents.Human umbilical vein endothelial cells
(Promocell) were used to recreate blood vessel lining in the
blood vessel model channel, and HeLa cells were used in to
create tumor spheroids. HUVECs were cultured in EndoGRO
Basal medium (Millipore) supplemented with SCME001 kit
(EndoGRO-LS Supplement 0.2%, rh EGF 5 ng/mL, ascorbic
acid 50 μg/mL, L-glutamine 10 mM, hydrocortisone hemi-
succinate 1 μg/mL, heparin sulfate 0.75 U/mL, FBS 2%), and
penicillin/streptomycin 1% (Biowest). HeLa cells were cultured
inDulbecco’s modified Eaglemedium (DMEM, as received with
L-glutamine, 4.5 g/L D-glucose and pyruvate, Gibco) supple-
mented with FBS 5% (Gibco) and penicillin/streptomycin 1%
(Biowest). HUVECs were cultured in 75 cm2 flasks and HeLa in
25 cm2 flasks at 37 °C and 5% CO2. Cells were harvested using
trypsin-EDTA (0.25%, Gibco) when they reached 70−80%
confluence.
Cell Culture in the Microfluidic Device. Collagen gel at
concentration of 2.5 mg/mL was prepared, introduced, and
polymerized according to the general protocol v5.3 (AIM
Biotech). In brief, Rat tail collagen Type I (Corning Life
Science) was mixed on ice with 10x PBS (Sigma-Aldrich) and
Phenol Red (Sigma-Aldrich), and the pH of the mixture was
adjusted to 7.4 using 0.5 M NaOH (NaOH in pellets PanReac
dissolved in MiliQ water); final volume was adjusted with MiliQ
water (for healthy model) or with suspension of HeLa clusters
(for cancer model).
For preparation of the cancer model, microfluidic chip HeLa
cells were seeded into a 96-well ultralow attachment plate
(Corning) at 0.5−1.5 k cells/well and cultured for 72 ± 24 h.
Formed cell spheroids were harvested, centrifuged, and
resuspended in previously prepared collagen gel, resulting in
few clusters (of 100 ± 50 μm) per 10 μL of the gel at the
concentration of 2.5 mg/mL. Prepared collagen was inserted
into the central channel of 3D culture chip and allowed to
polymerize during 30 min at 37 °C and 5% CO2. After gel
polymerization, one of the lateral channels was prepared for
HUVECs culture by coating the channel with 50 μg/mL
fibronectin (FN) from bovine plasma (Sigma-Aldrich) for 2 h at
37 °C and 5% CO2. The remaining lateral channel was filled in
with DMEM(HeLa culturemedium) and closed using luer caps.
After the incubation time, the FN was washed away using 1x
PBS (Gibco) and EndoGRO HUVEC medium. HUVECs were
seeded in the prepared lateral channel at a density of 2.5−3.5 M
cells/mL. The 3D culture chip was flipped upside down to allow
cell adhesion to the upper plane for 1.5−2.5 h at 37 °C and 5%
CO2. A second batch of HUVECs cultured in another flasks was
harvested and introduced to the same lateral channel at the same
concentration as previously. The cells were then incubated for
minimum 2 h at 37 °C and 5% CO2 in the upright position to
allow their attachment to the lower plane. Next, the chip was
perfused with EndoGRO HUVEC medium at a flow rate 3−5
μL/min for 48−72 h (as described above) until HUVECs
reached confluency.
Hybrids Perfusion Setup.Hybrids 1−4 were prepared at a
concentration of 480 μM in filtered PBS, sonicated for 5 min,
and let to equilibrate for at least 10 min. Prior to hybrid flowing
into the chip, they were mixed with full EndroGRO HUVEC
medium resulting in final concentration of 160 μM.
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The microfluidic chip was placed into the on-stage incubator
of a Zeiss LSM 800 confocal microscope at a temperature of 37
°C and 5% CO2, and connected to peristaltic pump (Ismatec,
Reglo Digital, ISM597) with a silicone tubing (Tygon, Kinesis)
to perfuse hybrids during real-time imaging at 15 μL/min.
Hybrids were excited using a 405 nm laser, and emission spectra
were collected using two different PMT detectors to detect both
monomer and micelle separately and simultaneously. The
windows of detection were set as follows: (i) monomer 446−
500 nm and (ii) micelle 500−700 nm. Ratiometric images were
obtained from dividing the micelle image by the monomer
image after a mask was applied to each image where noise was
removed.
To calculate the amount of hybrid able to extravasate, we first
summed up the signal of both windows. Next, we calculated the
mean intensity signal of the vessel channel and used this value as
the maximum concentration. Next the mean intensity signal of
the gel channel was calculated and divided by the maximum
signal concentration.
Dextran Perfusion. The 10 kDa Dextran labeled with
AlexaFluor568 (Thermo Fisher Scientific) was diluted in
HUVEC (EndoGRO) medium at a final concentration of 1
μg/mL. The solution was perfused into the blood vessel model
channel at a flow rate of 5 μL/min using the syringe pump. The
perfusion of dextran was monitored using Nikon Eclipse Ti2
epifluorescent microscope. The chip was placed in the on-stage
incubator (OKOlab) at a temperature of 37 °C and 5%CO2, the
perfused fluorophore was excited at 525 nm, and the emission
was collected at 650 nm.
HeLa Spheroid Viability Assay. The viability of HeLa cells
within the spheroids was evaluated using Calcein (Fluka, Sigma-
Aldrich) and propidium iodide (Sigma-Aldrich) to stain live and
dead cells, respectively. First, cells were incubated with 10 μM
Calcein solution for 20 min at 37 °C and 5%CO2. Next, the cells
were incubated with 10 μg/mL propidium iodide solution for 5
min at 37 °C and 5%CO2 and then washed with 1x PBS (Sigma-
Aldrich). The imaging was performed using a Zeiss LSM 800
confocal microscope. The Calcein and propidium iodide stained
spheroids were excited at laser wavelength of 488 and 561 nm,
respectively, and detection windows set at 400−600 nm for
Calcein and 600−700 nm for propidium iodide. The 3D image
was reconstructed (ZEN, confocal microscope software) from
slices acquired in a Z-stack mode with a plane interval of 1,5 μm.
Immunostaining, Labeling, and Confocal Microscopy
(Confocal Imaging Labeling). Cells in the microfluidic chip
were washed with 1x PBS (Gibco) and fixed with 4 wt % solution
of paraformaldehyde (PFA, Sigma-Aldrich) in 1x PBS. After 10
min, and the fixative was washed away with 1x PBS, cells were
permeabilized for 10 min with 0.1% solution of Triton X-100
(Sigma-Aldrich) in 1x PBS and exposed for 1 h to a 3% bovine
serum albumin (BSA, Sigma-Aldrich) blocking solution in 1x
PBS.
Next, the HUVECs’ tight junctions were stained using 5 μg/
mL ZO-1 (Zonula Occludens-1) monoclonal antibody con-
jugated with Alexa Fluor 488 (Thermo Fisher Scientific)
solution in previously prepared 3% BSA during O/N incubation
at 4 °C. In the next step, the cells were washed with 3% BSA
solution and incubated with 1x Phalloidin-iFluor594 (Abcam,
stock 1000x) solution (in 1% BSA) for 30 min at RT to stain
actin filaments. The cell nuclei were stained after washing the
cells with 1x PBS, using Hoechst 33258 stain at concentration 5
μg/mL. After 10 min of incubation at RT, the cells were washed
with 1x PBS and imaged at RT using a Zeiss LSM 800 confocal
microscope. Nuclei, tight junctions, and actin were excited using
a 405 nm, 488 nm, and 561 nm laser, respectively. The 3D
images were acquired scanning the sample in a Z-stack mode,
with an acquisition plane each 1 to 10 μm and later
reconstructed into 3D image using the ZEN (confocal
microscope) software.
To calculate the orientation of actin filaments in static versus
dynamic conditions, two independent chips were prepared as
explained; however, one of the chips was incubated in static
conditions, with medium change every 24 h; meanwhile, the
other was continuously perfused with cell medium. After 72 h,
the cells were fixed and actin stained, and confocal images of
actin were acquired using Zeiss LSM 800. The images were
analyzed using the OrientationJ plugin of ImageJ to obtain the
distribution of the orientation’s graphs.
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